To address this limitation, we conducted this systematic review and meta-analysis to update the literature on the effects of HER2-targeted therapy on survival, response, and safety outcomes in patients with HER2-positive breast cancer and IMD. The gene discussed is ERBB2; the disease is breast carcinoma.